Ask AI
ProCE Banner Activity

IMforte: Phase III Trial of Lurbinectedin + Atezolizumab vs Atezolizumab as First-line Maintenance Therapy in ES-SCLC

Conference Coverage
Slideset

In the phase III IMforte trial, first-line maintenance therapy with lurbinectedin + atezolizumab vs atezolizumab in patients with ES-SCLC and CR/PR/SD to induction therapy was associated with a meaningful improvement in IRF-PFS and OS, with a consistent safety profile for lurbinectedin + atezolizumab and no new safety signals.

Released: June 05, 2025

Expiration: December 04, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

PharmaMar